TB-500: the thymosin beta-4 fragment and what the evidence actually says

What is TB-500?

TB-500 is a product name, not a drug name. The active ingredient is a seven-amino-acid peptide, LKKTETQ, with an artificial acetyl group on its N-terminus. That sequence corresponds to residues 17–23 of thymosin beta-4 (Tβ4) — the segment responsible for actin binding, cell migration and wound healing.

The clearest chemical description of TB-500 in the peer-reviewed literature comes from an unlikely place: the racing laboratory of the Hong Kong Jockey Club. Their 2012 paper in Journal of Chromatography A describes TB-500 flatly as "a veterinary preparation" and sets out an LC–MS assay to detect it in horse urine and plasma. That paper exists because regulators needed to stop people giving it to racehorses — not because a clinical development program produced it. That origin story matters, and it is a fair summary of where TB-500 sits today.

Tβ4 itself is a genuine, well-studied human protein. It is one of the smallest and most abundant intracellular proteins, present in every cell type except erythrocytes, and platelets dump it at the site of an injury as part of the earliest repair cascade. Reviews describe it as a multi-functional regenerative peptide that reduces apoptosis, inflammation and scarring while mobilizing progenitor cells.

One naming point worth clearing up: thymosin beta-4 and thymosin alpha-1 are unrelated molecules despite the shared family name. Thymosin alpha-1 is a 28-amino-acid immunomodulator studied in sepsis and viral disease, and it is an approved drug in several countries. Tβ4 is a cytoskeletal protein studied in wound repair. They are not interchangeable, and marketing copy that treats them as siblings is wrong.

TB-500 vs thymosin beta-4: not the same molecule

This is the single most important distinction on the page, and most vendor pages get it wrong. Sellers routinely list TB-500 as "thymosin beta-4." Analytically, TB-500 contains 7 of the 43 amino acids in Tβ4 — roughly 16% of the molecule.

That difference is not cosmetic, because Tβ4's activities are spread across several distinct sites. A 2010 FASEB Journal review by Sosne and colleagues mapped the molecule's biology onto specific sequences:

• The N-terminal tetrapeptide Ac-SDKP generally blocks inflammation and reduces fibrosis.
• A 15-amino-acid N-terminal region that includes Ac-SDKP promotes cell survival and blocks apoptosis.
• The central actin-binding domain LKKTETQ (residues 17–23) promotes angiogenesis, wound healing and cell migration.

TB-500 supplies only the third of those. The anti-inflammatory and anti-fibrotic effects that make Tβ4 interesting as a repair molecule sit in a region TB-500 does not contain. So when a product page cites a Tβ4 study about reduced scarring and attributes it to TB-500, the citation does not survive contact with the sequence.

The second half of the problem is that essentially every human trial of this chemistry used full-length Tβ4, formulated topically. None used the fragment.

How does TB-500 work? The actin-binding mechanism

Actin is the protein cells use to build and dismantle their internal scaffolding. To migrate — which is what a cell has to do to close a wound or line a new capillary — a cell must rapidly convert monomeric G-actin into filaments and back. Tβ4 is the main G-actin sequestering protein in higher eukaryotes, holding a reserve pool of monomers ready for use.

Crystallography published in PNAS in 2014 showed exactly how it does this: Tβ4 uses two helices that clamp onto the barbed and pointed faces of a G-actin monomer, physically preventing it from joining a filament, and hands the monomer off to profilin when polymerization is needed. LKKTETQ is the contact motif at the heart of that interaction. The theory behind TB-500 is that supplying this motif alone accelerates the migration side of tissue repair.

The other frequently cited mechanism is signaling rather than structural. A 2004 Nature paper found that Tβ4 forms a complex with PINCH and integrin-linked kinase, activating the survival kinase Akt. After coronary artery ligation in mice, Tβ4 treatment increased ILK and Akt activity in the heart, improved early myocyte survival, and improved cardiac function. That result launched a decade of interest in Tβ4 as a post-infarction therapy. It has not produced an approved cardiac drug, and it was demonstrated with the whole protein in mice — not with a 7-amino-acid fragment in people.

Does TB-500 actually work?

For the fragment sold as TB-500, in humans, for any indication: there is no published randomized controlled trial. Search PubMed for TB-500 and the substantive hits are analytical chemistry papers about how to detect it in doping samples. That is the entire direct human literature.

What does exist is a genuine, if narrow, body of human evidence on full-length Tβ4, all of it topical. In ophthalmology, Tβ4 is well characterized as a corneal wound-healing and anti-inflammatory agent, and it has been developed as the eye drop RGN-259 through phase 2 and phase 3 trials. In dermatology, a review of the Tβ4 wound program reported that across two phase 2 trials in stasis and pressure ulcers, healing was accelerated by almost a month in the patients who healed.

Read that carefully. It is real evidence, and it is evidence for a different molecule, delivered to a surface, in patients with chronic non-healing wounds. It is not evidence that an injected fragment repairs a torn rotator cuff in a healthy 34-year-old.

Thymosin beta-4 human trials at a glance

Here is the actual human dataset behind this chemistry, alongside the gap where TB-500 evidence would sit.

Is there any evidence for injury and athletic recovery?

No. This is the use case that drives almost all consumer interest in TB-500, and it is the use case with the thinnest support.

To get from the published literature to "TB-500 heals my hamstring," a claim has to cross three gaps at once. It has to cross species, because most of the repair data is in rats and mice. It has to cross molecules, from the 43-amino-acid protein to the 7-amino-acid fragment. And it has to cross tissues, from cornea, skin and myocardium to tendon, ligament and skeletal muscle. Each of those jumps has broken plenty of promising compounds on its own. Together they mean the honest position is that nobody knows.

That is not the same as saying TB-500 is inert. The actin-binding motif is genuinely bioactive, and the biology is plausible. It means the effect size, the risk profile, and even whether an injected fragment reaches injured tendon in meaningful quantity are all unmeasured in humans.

TB-500 side effects: what is and isn't known

There is no controlled human safety study of TB-500. That is the accurate answer, and any page that gives you a confident side-effect list is describing forum reports, not monitored data.

What the trial literature offers is reassurance about a different exposure. In the phase 3 neurotrophic keratopathy study, no significant adverse effects were observed, and the phase 2 dry eye trial reported the drops were safe and well tolerated. Those are eye drops in a combined total of under 30 patients. The European venous ulcer program was explicitly built as a dose-escalation safety and tolerability study for the same reason: nobody had systemic human safety data then either.

Three concerns deserve to be named plainly rather than buried:

• Proliferation and angiogenesis. Tβ4's core functions — driving cell migration and new blood vessel formation — are processes tumors exploit. An in vivo CRISPR-Cas9 knockout screen identified the gene encoding Tβ4 as a promoter of diffuse-type gastric cancer metastasis. That is not evidence TB-500 causes cancer in people. It is a reason the question is open, and no human study has closed it.
• Product quality. TB-500 reaches consumers through research-chemical vendors with no pharmacopoeial oversight. The history of unregulated peptide analogues sold this way is not encouraging — the melanocortin analogue market produced documented harms tied to unregulated use, including cases traced to contaminated or misidentified product. Identity, purity and sterility are unverified by default.
• No long-term data. Repeated systemic administration of any growth-factor-like agent over months or years has no human safety record here at all.

Is TB-500 FDA approved or legal?

TB-500 has never been approved by the FDA, the EMA, or any comparable regulator, for any indication, in any country. Full-length thymosin beta-4 is investigational — it has an active ophthalmic development program and has reached phase 3, but investigational is not approved.

Two practical consequences follow. First, TB-500 is sold labeled "for research use only, not for human consumption," and that label is a legal shield for the seller, not an authorization for you. Second, thymosin beta-4 sits in FDA's category of bulk drug substances that raise significant safety concerns for compounding, which means a US compounding pharmacy cannot legally use it in a prepared medication. That closes the one legitimate-looking route consumers often assume exists.

None of that makes possession a criminal matter in most jurisdictions — it is not a controlled substance. The regulatory position is closer to "unapproved new drug" than "banned narcotic," and the practical rules vary considerably by country. Our overview of how peptide legality actually works covers the distinctions between approved, prescription-only, investigational and research-chemical status in more detail.

Is TB-500 banned in sport?

Yes, unambiguously. TB-500, thymosin beta-4, and derivatives fall under section S2 of the WADA Prohibited List, which covers peptide hormones, growth factors, related substances and mimetics — including growth factors that affect muscle, tendon or ligament protein synthesis, vascularization or regenerative capacity. Substances in S2 are prohibited at all times, both in and out of competition. There is no therapeutic-use loophole absent an approved TUE, and there is no approved indication to base one on.

The "it won't show up on a test" claim is also false. The Hong Kong Jockey Club method can confirm N-acetylated LKKTETQ at 0.02 ng/mL in plasma and 0.01 ng/mL in urine, and it was validated on real post-administration samples from horses given a single dose. Equine racing authorities banned TB-500 and thymosin beta-4 derivatives on the back of that work. Human anti-doping laboratories run comparable peptide-detection workflows.

TB-500 vs BPC-157

These two get marketed as a pair, usually as complementary halves of a recovery stack. The comparison is worth making precisely, because their evidence bases differ in shape rather than in strength.

BPC-157 is a 15-amino-acid sequence derived from a protein in gastric juice. Its animal literature is broader in exactly the tissues consumers care about — tendon, ligament, gut — but a 2025 narrative review titled "Regeneration or Risk?" and a companion analysis of its emerging use in orthopaedic sports medicine both land on the same conclusion: encouraging preclinical work, no controlled human efficacy trials, unresolved safety questions.

TB-500's advantage is that its parent molecule has been through real human trials, with a phase 3 readout and a defined structural mechanism. Its disadvantage is that TB-500 is not that molecule, and the human trials were topical, on tissues athletes are not treating. Neither peptide has been tested head-to-head against the other, and no trial has evaluated them combined. For a fuller side-by-side, see our BPC-157 vs TB-500 comparison and the standalone BPC-157 evidence review. If your interest is skin and connective tissue specifically, GHK-Cu has a different and in some ways better-documented literature.

Keeping a record if you are already using it

If you and a clinician have decided something is going into your body, the least you can do is document it accurately. With an unapproved compound and no established safety profile, a written record is the only signal you will ever have. What changed, when, and what happened afterward.

That means logging dates and what your clinician directed, noting where injections went and rotating sites rather than guessing from memory (see our guide to injection site considerations), and writing down symptoms with timestamps so a pattern is visible when you review it three months later. Our walkthrough on how to build a usable peptide log covers the mechanics. You can also browse the peptide Q&A library or the 16-entry starter library inside the app for PubMed-linked summaries on adjacent compounds.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry — J Chromatogr A, 2012. PubMed 23084823
2. Biological activities of thymosin beta4 defined by active sites in short peptide sequences — FASEB J, 2010. PubMed 20179146
3. Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization — PNAS, 2014. PubMed 25313062
4. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications — Expert Opin Biol Ther, 2012. PubMed 22074294
5. Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent — Clin Ophthalmol, 2007. PubMed 19668473
6. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair — Nature, 2004. PubMed 15565145
7. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial — Cornea, 2015. PubMed 25826322
8. 0.1% RGN-259 (thymosin β4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial — Int J Mol Sci, 2022. PubMed 36613994
9. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients — Ann N Y Acad Sci, 2012. PubMed 23050815
10. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing — Ann N Y Acad Sci, 2007. PubMed 17495250
11. In vivo CRISPR-Cas9 knockout screening using quantitative PCR identifies thymosin beta-4 X-linked that promotes diffuse-type gastric cancer metastasis — Mol Carcinog, 2021. PubMed 34081824
12. Regeneration or Risk? A Narrative Review of BPC-157 — 2025. PubMed 40789979
13. Emerging Use of BPC-157 in Orthopaedic Sports Medicine — 2025. PubMed 40756949
14. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues — 2017. PubMed 28266027
15. Thymosin alpha1 and its role in viral infectious diseases — 2023. PubMed 37110771

Keep reading